NCT06051045View on ClinicalTrials.gov

Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients

RecruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

March 31, 2033

Study Completion Date

March 31, 2033

Conditions
Chronic Hepatitis D
Interventions
DRUG

Bulevirtide

Hepcludex, 2 mg daily subcutaneous injection

Trial Locations (1)

Unknown

RECRUITING

Karolinska University Hospital, Department of Infectious Diseases, Stockholm

All Listed Sponsors
lead

Karolinska University Hospital

OTHER